Daiichi, AstraZeneca breast cancer drug joins bumper crop of early FDA approvals

The Food and Drug Administration on Friday approved Daiichi Sankyo and AstraZeneca's drug trastuzumab deruxtecan for heavily pretreated breast cancer, a decision that came more than three months ahead of the agency's deadline.